You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
With $6.5M in new funding, the Israeli bioinformatics startup is looking to open a US office as it builds relationships with pharma, cancer centers, and payors.
Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
The group will offer free access to omic and clinical data from the project and develop software to help clinicians use the models in patient care.
The partners have planned a three-year pilot and selected three NCI projects to benefit from supercomputers and expertise offered by four DOE labs.
Myriad Genetics, Kinaxo Biotechnologies, Bavarian Research Foundation, European Commission, Decode Genetics, Ontario Institute for Cancer Research
The $3.8 million program will back assay development, screening tools, toxicity, and elucidation of 3D structures in search of HIV treatments
The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.
The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.
A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.
In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.